Please login to the form below

Not currently logged in
Email:
Password:

Genfit

This page shows the latest Genfit news and features for those working in and with pharma, biotech and healthcare.

Genfit presses the gas on NASH with combo trials

Genfit presses the gas on NASH with combo trials

It will enrol patients with suspected NASH and significant to advanced fibrosis, measured using non-invasive diagnostic tools including Genfit’s own NIS4 diagnostic test for NASH. ... Dean Hum. “NASH is a multifaceted cardio-metabolic disease

Latest news

  • Genfit claims FDA breakthrough status for liver disease drug Genfit claims FDA breakthrough status for liver disease drug

    Elafibranor has shown promising anticholestatic effects in a Phase 2 clinical trial,” said Pascal Birman, Deputy Chief Medical Officer, Genfit. ... Genfit’s drug has been shown to reduce this however, operating as a dual agonist of the peroxisome

  • Genfit launches $135m IPO to back NASH plans Genfit launches $135m IPO to back NASH plans

    Trailing rivals Intercept in race to market. Genfit has priced its initial public offering (IPO) in the US as it looks to raise $135m to help advance its drug for ... Another $35m earmarked for pivotal trials in primary biliary cirrhosis, a rare

  • Liver specialist Genfit files $120m IPO on Nasdaq Liver specialist Genfit files $120m IPO on Nasdaq

    French biotech Genfit has pressed the button on a public listing in the US, seeking to raise around $120m to help it fund development of lead liver disease drug elafibranor. ... Genfit is offering five million shares at $26.33 on the Nasdaq Global Market

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Other competition is coming from pharma heavyweights Novartis and Pfizer, which recently joined forces to test three drugs in combination, and other clinical-stage player such as Allergan, Viking, Genfit, Novo

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Intercept’s Ocaliva (obeticholic acid, an FXR agonist) and Genfit’s elafibranor (PPAR α and δ agonist) are already in phase 3, but have made slow progress, leaving the door open

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics